SCHEMBL22446776

SCHEMBL22446776

C[C@H](CCC(C)(C)O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@@H](O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ OSBP P22059 1/20 0.70
▸ OSBP2 Q969R2 1/20 0.70
▸ GPBAR1 Q8TDU6 7/20 0.54
▸ CASP7 P55210 3/20 0.54
▸ HIF1A Q16665 3/20 0.54
▸ TP53 P04637 2/20 0.54
▸ MAPK1 P28482 2/20 0.54
▸ HSD17B10 Q99714 2/20 0.54
▸ BLM P54132 2/20 0.54
▸ TDP1 Q9NUW8 2/20 0.54
▸ VDR P11473 2/20 0.54
▸ USP2 O75604 2/20 0.54
▸ CYP3A4 P08684 2/20 0.54
▸ LMNA P02545 2/20 0.54
▸ EPHA2 P29317 2/20 0.54
▸ MDM4 O15151 1/20 0.54
▸ MAPT P10636 1/20 0.54
▸ HSPD1 P10809 1/20 0.54
▸ TSHR P16473 1/20 0.54
▸ PTPN2 P17706 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14770971 0.87 OSBP (0.90) OSBPOSBP2GPBAR1CASP7HIF1A
SCHEMBL24766041 0.87 OSBP (0.90) OSBPOSBP2GPBAR1CASP7HIF1A
SCHEMBL31145625 0.87 OSBP (0.90) OSBPOSBP2GPBAR1CASP7HIF1A
SCHEMBL23373110 0.87 OSBP (0.90) OSBPOSBP2GPBAR1CASP7HIF1A
SCHEMBL16786313 0.87 OSBP (0.90) OSBPOSBP2GPBAR1CASP7HIF1A
SCHEMBL16225880 0.87 GPBAR1 (0.55) OSBPOSBP2GPBAR1CASP7HIF1A
SCHEMBL16226126 0.87 GPBAR1 (0.55) OSBPOSBP2GPBAR1CASP7HIF1A
SCHEMBL16226151 0.87 OSBP (0.59) OSBPOSBP2GPBAR1CASP7HIF1A
SCHEMBL16226858 0.87 GPBAR1 (0.55) OSBPOSBP2GPBAR1CASP7HIF1A
SCHEMBL6558598 0.87 OSBP (0.59) OSBPOSBP2GPBAR1CASP7HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210147468-A1 OXYSTEROLS AND METHODS OF USE THEREOF SAGE THERAPEUTICS, INC. 2021-05-20 — — US disclosed
EP-3481846-B1 11-SUBSTITUTED 24-HYDROXYSTEROLS FOR USE IN THE TREATMENT OF NMDA RELATED CONDITIONS SAGE THERAPEUTICS INC (US) 2021-05-12 — — EP disclosed
US-10781231-B2 Oxysterols and methods of use thereof SAGE THERAPEUTICS, INC. (US) 2020-09-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10781231-B2 Oxysterols and methods of use thereof HSD3B1, CYP17A1, HSD17B7 OSBP 97/4885OSBP2 113/4885GPBAR1 98/4885
US-20210147468-A1 OXYSTEROLS AND METHODS OF USE THEREOF HSD3B1, CYP17A1, HSD17B7 OSBP 98/4885OSBP2 123/4885GPBAR1 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback